Your session is about to expire
← Back to Search
Study Summary
This trial is testing a biomarker that may predict which patients with Pure Autonomic Failure (PAF) will convert to Parkinson's disease (PD), Multiple System Atrophy (MSA), or Dementia with Lewy Bodies (DLB). The biomarker is related to the neurotransmitter dopamine.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I have been diagnosed with pure autonomic failure.Medical examination confirming the diagnosis.You have any kind of metal implant that could move because of the magnetic field.I am under 18 years old.You cannot be pregnant because we don't know how the strong MRI machine could affect the baby.I am 18 years old or older and in good health.You have metal clips in your brain to treat an aneurysm.I am able to understand and give consent for my treatment.I have a condition that affects my body's automatic functions and may have Parkinson's, MSA, or DLB.You have metal fragments in your body, for example, from a war injury or from working with metal.
- Group 1: [18F]F-DOPA
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many test subjects are being included in this experiment?
"Affirmative. According to the information on clinicaltrials.gov, this study is currently recruiting patients which began on February 4th 2020 and was recently updated on April 14 2022. The trial requires 40 participants from one center of care."
How is [18F]FDOPA typically employed to assist patients?
"[18F]FDOPA is regularly employed to treat Parkinson's disease and its associated complications, including the wearing off effect, carbon monoxide intoxication, and post encephalitic parkinsonism."
Are participants currently being recruited for this research endeavor?
"As per clinicaltrials.gov, this research project is actively searching for participants. The trial was initially advertised on February 4th 2020 and had its most recent update recorded on April 14th 2022."
How have patients responded to [18F]FDOPA as a therapeutic agent?
"Due to the fact that this is Phase 1 trial, with limited clinical data for [18F]FDOPA's safety and efficacy, our team at Power has conservatively rated its safety on a scale of 1-3 as a '1'."
Is there any precedent for utilizing [18F]FDOPA in research?
"Currently, 15 [18F]FDOPA trials are operational with 4 of them in their final phase. 227 sites have been set up to run these clinical studies, a prominent one being located in Chicago, Illinois."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger